Furthermore, in one large evaluation, the OnTARGET trial (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial), the combination of an ACE inhibitor and an angiotensin receptor blocker (ARB) was no better than an ACE inhibitor alone, and increased the risk of adverse effects.
基于1个网页-相关网页
应用推荐